Titan Pharmaceuticals, Inc.

NasdaqCM TTNP

Titan Pharmaceuticals, Inc. Free Cash Flow for the Trailing 12 Months (TTM) ending September 30, 2024

Titan Pharmaceuticals, Inc. Free Cash Flow is NA for the Trailing 12 Months (TTM) ending September 30, 2024. Free cash flow is the amount of cash a company generates after accounting for cash outflows to support operations and maintain its capital assets.

Titan Pharmaceuticals, Inc. Free Cash Flow for the Trailing 12 Months (TTM) ending September 30, 2022 was USD -7.69 M.
Titan Pharmaceuticals, Inc. Free Cash Flow for the Trailing 12 Months (TTM) ending September 30, 2020 was USD -16.95 M, a -8.79% change year over year.

Key data

Date	Free Cash Flow	Operating Cash Flow	Net Cash Used For Investing Activities	Net Cash Used Provided By Financing Activities

NasdaqCM: TTNP

Titan Pharmaceuticals, Inc.

CEO	Mr. Brynner Chiam
IPO Date	Jan. 18, 1996
Location	United States
Headquarters	400 Oyster Point Boulevard
Employees	4
Sector	Health Care
Industries Pharmaceuticals

Description

Titan Pharmaceuticals, Inc., a pharmaceutical company, develops therapeutics for the treatment of chronic diseases. It develops products based on ProNeura, a proprietary long-term drug delivery platform. The company offers Probuphine implant for the maintenance treatment of opioid use disorder in clinically stable patients in Canada and the European Union. It is also developing kappa opioid agonist peptide program (TP-2021) for use in combination with ProNeura technology for the treatment of chronic pruritus; nalmefene implant program for the prevention of opioid relapse following detoxification of patients suffering opioid use disorder; and other programs, including HIV preventative therapeutic and a contraceptive from a single ProNeura implant for women and adolescent girls. The company was incorporated in 1992 and is based in South San Francisco, California.

Key trends

Past 5 years